HER2 Heterogeneity Is Associated with Poor Survival in HER2-Positive Breast Cancer

被引：30

作者：

Hosonaga, Mari ^{[1
]}

Arima, Yoshimi ^{[2
]}

Sampetrean, Oltea ^{[2
]}

Komura, Daisuke ^{[3
]}

Koya, Ikuko ^{[4
]}

Sasaki, Takashi ^{[5
]}

Sato, Eiichi ^{[6
]}

Okano, Hideyuki ^{[4
]}

Kudoh, Jun ^{[7
]}

Ishikawa, Shumpei ^{[3
]}

Saya, Hideyuki ^{[2
]}

Ishikawa, Takashi ^{[1
]}

机构：

[1] Tokyo Med Univ, Dept Breast Surg & Oncol, Shinjuku Ku, 6-7-1 Nishishinjuku, Tokyo 1600023, Japan

[2] Keio Univ, Inst Adv Med Res, Div Gene Regulat, Sch Med,Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan

[3] Tokyo Med & Dent Univ, Med Res Inst, Dept Genom Pathol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan

[4] Keio Univ, Dept Physiol, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan

[5] Keio Univ, Ctr Supercentenarian Med Res, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan

[6] Tokyo Med Univ, Inst Med Sci, Dept Pathol, Med Res Ctr,Shinjuku Ku, 6-7-1 Nishishinjuku, Tokyo 1600023, Japan

[7] Keio Univ, Lab Gene Med, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2018年 / 19卷 / 08期

关键词：

HER2; heterogeneity; breast cancer; poor prognosis; caspase-1; GENE AMPLIFICATION; INTRATUMORAL HETEROGENEITY; CELLS; CARCINOMAS; EXPRESSION; CASPASE-1; EVOLUTION; IMPACT;

D O I：

10.3390/ijms19082158

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Intratumoral human epidermal growth factor receptor 2 (HER2) heterogeneity has been reported in 16-36% of HER2-positive breast cancer and its clinical impact is under discussion. We examined the biological effects of HER2-heterogeneity on mouse models and analyzed metastatic brains by RNA sequence analysis. A metastatic mouse model was developed using 231-Luc (triple negative cells) and 2 HER2-positive cell lines, namely, HER2-60 and HER2-90 which showed heterogeneous and monotonous HER2 expressions, respectively. Metastatic lesions developed in 3 weeks in all the mice injected with HER2-60 cells, and in 69% of the mice injected with HER2-90 and 87.5% of the mice injected with 231-Luc. The median survival days of mice injected with 231-Luc, HER2-60, and HER2-90 cells were 29 (n = 24), 24 (n = 22) and 30 (n = 13) days, respectively. RNA sequence analysis showed that CASP-1 and its related genes were significantly downregulated in metastatic brain tumors with HER2-60 cells. The low expression of caspase-1 could be a new prognostic biomarker for early relapse in HER2-positive breast cancer.

引用

页数：12

共 50 条

[21] Novel Peptidomimetics for Inhibition of HER2:HER3 Heterodimerization in HER2-Positive Breast Cancer
Kanthala, Shanthi
Banappagari, Sashikanth
Gokhale, Ameya
Liu, Yong-Yu
Xin, Gu
Zhao, Yunfeng
Jois, Seetharama
CHEMICAL BIOLOGY & DRUG DESIGN, 2015, 85 (06) : 702 - 714
[22] Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
Advani, Pooja
Cornell, Lauren
Chumsri, Saranya
Moreno-Aspitia, Alvaro
BREAST CANCER-TARGETS AND THERAPY, 2015, 7 : 321 - 335
[23] Temporal Heterogeneity of HER2 Expression and Spatial Heterogeneity of 18F-FDG Uptake Predicts Treatment Outcome of Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer
Gong, Chengcheng
Liu, Cheng
Tao, Zhonghua
Zhang, Jian
Wang, Leiping
Cao, Jun
Zhao, Yannan
Xie, Yizhao
Hu, Xichun
Yang, Zhongyi
Wang, Biyun
CANCERS, 2022, 14 (16)
[24] Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer
Yoshioka, Takahiro
Shien, Kazuhiko
Namba, Kei
Torigoe, Hidejiro
Sato, Hiroki
Tomida, Shuta
Yamamoto, Hiromasa
Asano, Hiroaki
Soh, Junichi
Tsukuda, Kazunori
Nagasaka, Takeshi
Fujiwara, Toshiyoshi
Toyooka, Shinichi
CANCER SCIENCE, 2018, 109 (04) : 1166 - 1176
[25] Targeting Chromosomal Instability and Tumour Heterogeneity in HER2-Positive Breast Cancer
Burrell, Rebecca A.
Juul, Nicolai
Johnston, Stephen R.
Reis-Filho, Jorge S.
Szallasi, Zoltan
Swanton, Charles
JOURNAL OF CELLULAR BIOCHEMISTRY, 2010, 111 (04) : 782 - 790
[26] HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
Kurozumi, Sasagu
Padilla, Mary
Kurosumi, Masafumi
Matsumoto, Hiroshi
Inoue, Kenichi
Horiguchi, Jun
Takeyoshi, Izumi
Oyama, Tetsunari
Ranger-Moore, Jim
Allred, D. Craig
Dennis, Eslie
Nitta, Hiroaki
BREAST CANCER RESEARCH AND TREATMENT, 2016, 158 (01) : 99 - 111
[27] HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
Blancas, Isabel
Linares-Rodriguez, Marina
Martin-Bravo, Celia
Gomez-Pena, Celia
Rodriguez-Serrano, Fernando
CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (10) : 2531 - 2540
[28] HER2 Intratumoral Heterogeneity in Breast Cancer, an Evolving Concept
Hou, Yanjun
Nitta, Hiroaki
Li, Zaibo
CANCERS, 2023, 15 (10)
[29] Novel HER2 Aptamer Selectively Delivers Cytotoxic Drug to HER2-positive Breast Cancer Cells in Vitro
Liu, Zhe
Duan, Jin-Hong
Song, Yong-Mei
Ma, Jie
Wang, Feng-Dan
Lu, Xin
Yang, Xian-Da
JOURNAL OF TRANSLATIONAL MEDICINE, 2012, 10
[30] The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells
Sahlberg, Kristine Kleivi
Hongisto, Vesa
Edgren, Henrik
Makela, Rami
Hellstrom, Kirsi
Due, Eldri U.
Vollan, Hans Kristian Moen
Sahlberg, Niko
Wolf, Maija
Borresen-Dale, Anne-Lise
Perala, Merja
Kallioniemi, Olli
MOLECULAR ONCOLOGY, 2013, 7 (03) : 392 - 401

← 1 2 3 4 5 →